20 1 20 6 21 0 21 4 22 7 23 1 and 23 6 and an infrared spectrum having sharp bands at 2925 2854 1637 1604 1484 1395 1375 1285 1230 1172 1125 1082 999 943 893 868 860 782 705 684 cm u2212 1 and wherein the extrapolated melting point is 137 2 u00b0 c application_number US 76612204 A description it has been found that 2 3 5 bis trifluoromethyl phenyl n 6 1 1 dioxo 1 u03bb 6 thiomorpholin 4 yl 4 4 fluoro 2 methyl phenyl pyridin 3 yl n methyl isobutyramide can be isolated depending upon the method of preparation in 3 different crystalline modifications a b and c and in amorphous form which are distinguishable by their infra red spectra x ray powder diffraction patterns and their melting behaviour it also has been found that the a modification of the above mentioned compound has an improved pharmaceutical profile especially in the case of oral administration the compound can be formulated at high concentrations in a composition further comprising certain selected adjuvants such formulations have a better substance resorption and thus an improved bioavailability compared with formulations which contain 2 3 5 bis trifluoromethyl phenyl n 6 1 1 dioxo 1 u03bb 6 thiomorpholin.